FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 2. 股份分類 | 普通股 | 股份 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 公司名稱: 北京市春立正達醫療器械股份有限公司 呈交日期: 2025年12月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01858 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 95,140,500 | RMB | | 1 RMB | | 95,140,500 | | 2. 股份分類 | 普通 ...

Core Viewpoint - The stock of Chunli Medical (688236) has shown a decline in price and mixed capital flow, indicating potential volatility in investor sentiment and market performance [1][2]. Financial Performance - As of December 2, 2025, Chunli Medical's stock closed at 24.31 yuan, down 0.86% with a trading volume of 9,241 hands and a transaction value of 22.5152 million yuan [1]. - In the last five days, the stock experienced fluctuations in capital flow, with a net outflow of 218.06 million yuan from main funds on December 2, 2025, while retail investors saw a net outflow of 140.51 million yuan [2]. - For the first three quarters of 2025, Chunli Medical reported a main revenue of 756 million yuan, a year-on-year increase of 48.75%, and a net profit of 192 million yuan, up 213.21% year-on-year [3]. Industry Comparison - Chunli Medical's total market value is 9.325 billion yuan, which is below the industry average of 11.042 billion yuan, ranking 38 out of 124 in the medical device sector [3]. - The company has a gross margin of 67.27%, significantly higher than the industry average of 51.22%, and a net profit margin of 25.34%, compared to the industry average of 9.57% [3]. Analyst Ratings - In the past 90 days, 8 institutions have rated Chunli Medical, with 7 buy ratings and 1 hold rating, indicating a generally positive outlook among analysts [4]. - The average target price set by institutions for the stock is 31.8 yuan, suggesting potential upside from the current trading price [4].

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant financial performance with a notable increase in revenue and net profit, indicating strong growth potential in the orthopedic medical device sector [2][3] - As of September 30, 2025, Spring Medical achieved an operating income of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [2] - The company has a high financing balance of 40.56 million yuan, which accounts for 0.57% of its market capitalization, indicating a strong position in the market [1] Group 2 - Spring Medical primarily engages in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prostheses and spinal implants [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2]

Group 1 - The core point of the article highlights that southbound funds have reduced their holdings in Spring Medical (01858.HK) by 13,200 shares on December 1, 2025, marking a cumulative net reduction of 644,200 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have reduced their holdings in Spring Medical on 11 occasions, resulting in a total net reduction of 283,800 shares [1] - As of the latest data, southbound funds hold 43,889,800 shares of Spring Medical, which accounts for 46.12% of the company's total issued ordinary shares [1] Group 2 - Spring Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implant products [2] - The company's joint prosthetic products cover four major human joints: hip, knee, shoulder, and elbow, while its spinal implant products consist of a full range of spinal fixation systems [2] - Spring Medical's products are exported to various countries and regions across Asia, South America, Africa, Oceania, and Europe [2]

Group 1 - The stock of Chunli Medical (688236) closed at 24.52 yuan on December 1, 2025, with a slight increase of 0.25% and a turnover rate of 0.51% [1] - The net inflow of main funds on December 1 was 969,700 yuan, accounting for 2.67% of the total transaction amount, while retail investors had a net inflow of 910,300 yuan, representing 2.51% [1] - Over the past five days, the stock has shown fluctuations in fund flows, with notable net inflows and outflows from different investor categories [1] Group 2 - Chunli Medical's total market value is 9.405 billion yuan, which is below the industry average of 11.157 billion yuan, ranking 38 out of 124 in the medical device sector [2] - The company reported a net profit of 192 million yuan for the first three quarters of 2025, reflecting a significant year-on-year increase of 213.21%, with a gross margin of 67.27% [2] - The third quarter of 2025 saw a remarkable 109.51% year-on-year increase in main revenue, reaching 268 million yuan, and a net profit of 77.06 million yuan, up 531.12% year-on-year [2] Group 3 - In the last 90 days, 8 institutions have rated the stock, with 7 buy ratings and 1 hold rating, and the average target price set at 31.8 yuan [3]

Core Viewpoint - Spring Medical is a leading domestic orthopedic medical device manufacturer focusing on the research, production, and sales of implantable orthopedic medical devices, including dental metal and invisible orthodontics, with ongoing development of customized dental implants [2][3] Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is located in Tongzhou District, Beijing, specializing in implantable orthopedic medical devices [7][8] - The company's main products include joint prosthetics and spinal implants, covering major human joints such as hip, knee, shoulder, and elbow, as well as a full range of spinal fixation systems [8] Financial Performance - For the period from January to September 2025, Spring Medical achieved revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a year-on-year increase of 213.21% [8] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan in the last three years [8] Market Position and Recognition - Spring Medical has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, which is a prestigious title for small and medium-sized enterprises in China, indicating strong innovation capabilities and high market share [3] - The company is positioned within the pharmaceutical and biological industry, specifically in the medical device sector, and is involved in various concept sectors including dental medical, financing, and robotics [8] Shareholder Information - As of September 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited and other new entrants, indicating a diversification in shareholder base [9]

来源：新浪证券-红岸工作室 11月28日，春立医疗涨0.49%，成交额3195.81万元。两融数据显示，当日春立医疗获融资买入额535.08 万元，融资偿还307.67万元，融资净买入227.41万元。截至11月28日，春立医疗融资融券余额合计 4193.37万元。 截至9月30日，春立医疗股东户数6164.00，较上期增加4.12%；人均流通股46906股，较上期减少 3.95%。2025年1月-9月，春立医疗实现营业收入7.56亿元，同比增长48.75%；归母净利润1.92亿元，同 比增长213.21%。 分红方面，春立医疗A股上市后累计派现3.59亿元。近三年，累计派现3.09亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 融资方面，春立医疗当日 ...

Core Viewpoint - The company, Beijing Chunli Zhengda Medical Instrument Co., Ltd., is set to hold a Q3 2025 performance briefing on December 8, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing will take place on December 8, 2025, from 10:00 AM to 11:00 AM [5]. - The location for the meeting is the Shanghai Stock Exchange Roadshow Center, accessible online [4][5]. - The meeting will be conducted in an interactive online format, allowing for real-time communication with investors [3][4]. Group 2: Investor Participation - Investors can submit questions for the briefing from December 1 to December 5, 2025, by visiting the Shanghai Stock Exchange Roadshow Center website or via the company's email [6]. - The company will address commonly asked questions during the briefing [2][6]. - After the meeting, investors can review the session's details and key content on the Shanghai Stock Exchange Roadshow Center [6].

格隆汇11月28日丨春立医疗(01858.HK)公告，北京市春立正达医疗器械股份有限公司已于2025年10月31 日发布公司2025年第三季度报告，为便于广大投资者更全面深入地了解公司2025年第三季度经营成果、 财务状况，公司计划于2025年12月8日上午10:00-11:00举行2025年第三季度业绩说明会，就投资者关心 的问题进行交流。 ...